NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 997 coverWomen's Health and Disease: Gynecologic and Reproductive Issues Volume 997 published November 2003
Ann. N.Y. Acad. Sci. 997: 322 (2003). doi: 10.1196/annals.1290.035
Copyright © 2003 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by DIAMANTI-KANDARAKIS, E.
Articles by KANDARAKIS, H. A.
Search for Related Content
PubMed
PubMed Citation
Articles by DIAMANTI-KANDARAKIS, E.
Articles by KANDARAKIS, H. A.
Conservative Management of Gynecologic Diseases

Insulin Sensitizing Agents in Polycystic Ovary Syndrome

EVANTHIA DIAMANTI-KANDARAKISa AND HELEN A. KANDARAKISb

aUniversity of Athens Medical School, Athens, Greece
bTorvegata Medical School, University of Rome, Rome, Italy

Address for correspondence: E. Diamanti-Kandarakis, Associate Professor of Medicine, University of Athens Medical School, 1A-Zefyrou Ekali 145-78, Thens, Greece. Fax: 30-210-8130031.
akandara{at}otenet.gr
Ann. N.Y. Acad. Sci. 997: 322-329 (2003).

A contemporary "Pandora's box" could be the polycystic ovary syndrome (PCOS), containing several negative features for a woman: compromised looks, compromised fertility; increased metabolic risk factors; and compromised general health. During the past decate, the central importance of insulin resistance (IR) in the pathogenesis of this syndrome has been established. Several in vivo and in vitro studies have demonstrated this phenomenon, initially by the hyperinsulinemic response to oral glucose in obese and lean women with PCOS compared with weight-matched normal women, and subsequently with more sensitive techniques like euglycemic hyperinsulinemic clamp. In vitro studies have corroborated these findings, showing molecular defects at the postreceptor level of insulin action, such as increased serine phosphorylation and decreased phospoinositol 3-kinase action. Insulin sensitizers are the group of therapeutic agents that hold some promise of helping women with polycystic ovary syndrome (PCOS), since the role of insulin resistance and hyperinsulinemia appear to be major contributors to the pathophysiology of the syndrome. The therapeutic approach with insulin sensitizers appears to have benefitial effects on the metabolic as well as on the reproductive abnormalities in women affected by PCOS. Finally, insulin sensitizers should be considered by all subspecialists who aim at a comprehensive management of patients with PCOS.

Key Words: gynecologic diseases • insulin-sensitizing agents • polycystic ovary syndrome (PCOS)






footerLeft footerRight